Overexpression of microRNA-29b inhibits epithelial-mesenchymal transition and angiogenesis of colorectal cancer through the ETV4/ERK/EGFR axis

Table 2 Relationships between miR-29b expression and clinicopathological features of CRC patients

Clinicopathological feature	Case	miR-29b expression	p	EVT4 expression	p
Age (years)
< 60	35	0.56 ± 0.15	0.476	2.40 ± 0.31	0.493
≥ 60	41	0.54 ± 0.09	0.476	2.44 ± 0.19	0.493
Gender
Male	54	0.55 ± 0.12	0.999	2.42 ± 0.26	0.877
Female	22	0.55 ± 0.11	0.999	2.43 ± 0.24	0.877
Tumor location
Colon	29	0.57 ± 0.10	0.310	2.39 ± 0.22	0.404
Rectum	47	0.54 ± 0.13	0.310	2.44 ± 0.27	0.404
Tumor size (cm)
< 5	41	0.53 ± 0.09	0.137	2.45 ± 0.20	0.302
≥ 5	35	0.57 ± 0.14	0.137	2.39 ± 0.30	0.302
Differentiation grade
Well/moderate	49	0.62 ± 0.09	< 0.001	2.28 ± 0.17	< 0.001
Poor	27	0.42 ± 0.05	< 0.001	2.68 ± 0.12	< 0.001
LNM
No	40	0.65 ± 0.07	< 0.001	2.23 ± 0.16	< 0.001
Yes	36	0.44 ± 0.06	< 0.001	2.63 ± 0.13	< 0.001
TNM staging
I/II	33	0.67 ± 0.06	< 0.001	2.19 ± 0.14	< 0.001
III/IV	43	0.46 ± 0.07	< 0.001	2.60 ± 0.14	< 0.001

CRC, colorectal cancer; miR-29b, microRNA-29b; ETV4, ETS variant 4; LNM, lymph node metastasis; TNM, tumor node metastasis